Dexpramipexole

Generic Name: Dexpramipexole

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N_₃S

CAS Number: 104632-28-2

Unique Ingredient Identifier: WI638GUS96

Background: Dexpramipexole is under investigation in clinical trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)).

Clinical Trials

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

Phase 2

Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Dexpramipexole Dihydrochloride

First Posted Date: 2024-08-01

Last Posted Date: 2025-05-14

Lead Sponsor: Areteia Therapeutics

Target Recruit Count: 30

Registration Number: NCT06533553

Locations: 🇺🇸
Research Site US-10001-017, Conway, Arkansas, United States
🇺🇸
Research Site US-10001-008, Newport Beach, California, United States
🇺🇸
Research Site US-10001-022, Northridge, California, United States

and more 20 locations

Phase III Long-Term Extension Study With Dexpramipexole

Phase 3

Conditions: Eosinophilic Asthma

Interventions: Drug: Dexpramipexole Dihydrochloride

First Posted Date: 2024-04-29

Last Posted Date: 2025-05-22

Lead Sponsor: Areteia Therapeutics

Target Recruit Count: 1600

Registration Number: NCT06388889

Locations: 🇵🇱
Research Site 20048-010, Piaseczno, Poland
🇵🇱
Research Site 20048-008, Piuria, Poland
🇵🇱
Research Site 20048-018, Bialystok, Poland

and more 59 locations

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

Phase 3

Recruiting

Conditions: Asthma; Eosinophilic
Eosinophilic Asthma
Asthma

Interventions: Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

First Posted Date: 2023-04-14

Last Posted Date: 2025-05-14

Lead Sponsor: Areteia Therapeutics

Target Recruit Count: 930

Registration Number: NCT05813288

Locations: 🇩🇪
Research Site 30049-004, Cottbus, Germany
🇩🇪
Research Site 30049-082, Delitzsch, Germany
🇩🇪
Research Site 30049-059, Frankfurt, Germany

and more 246 locations

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

Phase 3

Recruiting

Conditions: Eosinophilic Asthma
Asthma
Asthma; Eosinophilic

Interventions: Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

First Posted Date: 2023-03-10

Last Posted Date: 2025-05-14

Lead Sponsor: Areteia Therapeutics

Target Recruit Count: 1395

Registration Number: NCT05763121

Locations: 🇯🇵
Research Site 20081-031, Shizuoka, Japan
🇯🇵
Research Site 20081-061, Shizuoka, Japan
🇯🇵
Research Site 20081-034, Tokyo, Japan

and more 326 locations

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

Phase 3

Active, not recruiting

Conditions: Eosinophilic Asthma
Asthma; Eosinophilic
Asthma Attack

Interventions: Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

First Posted Date: 2023-02-28

Last Posted Date: 2025-05-14

Lead Sponsor: Areteia Therapeutics

Target Recruit Count: 550

Registration Number: NCT05748600

Locations: 🇧🇷
Research Site 40055-035, Rio de Janeiro, Brazil
🇧🇷
Research Site 40055-025, Salvador, Brazil
🇧🇷
Research Site 40055-005, Santo André, Brazil

and more 316 locations

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Phase 2

Completed

Conditions: Eosinophilic Asthma
Asthma

Interventions: Drug: Placebo
Drug: Dexpramipexole

First Posted Date: 2019-08-06

Last Posted Date: 2023-04-13

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 534

Registration Number: NCT04046939

Locations: 🇺🇸
Research Site, El Paso, Texas, United States
🇺🇸
Research site, Plymouth, Minnesota, United States

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

Phase 2

Completed

Conditions: Chronic Sinusitis With Nasal Polyps and Eosinophilia

Interventions: Drug: dexpramipexole

First Posted Date: 2014-08-15

Last Posted Date: 2021-05-18

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 20

Registration Number: NCT02217332

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
🇺🇸
ENT Associates of South Florida, Boca Raton, Florida, United States

and more 4 locations

Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome

Phase 2

Conditions: Hypereosinophilic Syndrome

Interventions: Drug: Dexpramipexole

First Posted Date: 2014-04-02

Last Posted Date: 2017-12-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 15

Registration Number: NCT02101138

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase 3 Extension Study of Dexpramipexole in ALS

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Dexpramipexole

First Posted Date: 2012-06-18

Last Posted Date: 2022-05-03

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 616

Registration Number: NCT01622088

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
ALS Center at Penn, Philadelphia, Pennsylvania, United States

and more 77 locations

Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Dexpramipexole

First Posted Date: 2012-05-28

Last Posted Date: 2014-11-25

Lead Sponsor: Knopp Biosciences

Target Recruit Count: 24

Registration Number: NCT01607034

Locations: 🇺🇸
Research Site, St. Paul, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy